Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

December 15, 2015December 15, 2015

Cystic Fibrosis Study Planned for Adults with Diabetes and Liver Disease

Cystic Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company developing bioseparations, plasma-derived therapeutics and small-molecule therapies, announced this week that it is planning to commence a Phase 2 double-blind, placebo-controlled clinical trial of its ... Read more

December 10, 2015

UK COPD Study Highlights High Costs and Burdens of Treatment

COPD, News

A recent study in the journal Respiratory Research notes the high costs and burdens of chronic obstructive pulmonary disease treatment among patients initiating maintenance therapy, and the low rates of patient adherent to treatment. ... Read more

December 10, 2015December 10, 2015

Phase 3 Trial for Systemic Sclerosis with Lung Fibrosis Enrolls 1st Patient

News, Scleroderma

Boehringer Ingelheim announced the enrollment of the first patient in its global, double-blind, randomized and placebo-controlled SENSCIS Phase 3 clinical trial. The trial (NCT02597933), is open for patient recruitment, and is evaluating the safety ... Read more

December 8, 2015December 8, 2015

PAH Therapy with Preservative-free Trevyent Shows Promise in Easing Pain

News, Pulmonary Hypertension

SteadyMed Ltd., a pharmaceutical company focused on developing drugs for the treatment of orphan and high value diseases, has announced positive data from an animal study assessing the clinical effects of its Trevyent® (preservative-free ... Read more

December 7, 2015December 7, 2015

COPD Patients’ Mental Health Can Affect Life Quality, Too

COPD, News

The results of a recent study published in the journal Psychology & Health show that psychological factors — such as illness perception and an internal locus of control — can influence health-related quality of ... Read more

November 25, 2015November 30, 2015

Eli Lilly Therapy for Metastatic Squamous NSCLC Gets FDA Approval

Lung Cancer, News

A novel treatment for a particularly deadly form of lung cancer has just been approved by the U.S. Food and Drug Administration (FDA) — Eli Lilly and Company‘s Portrazza (necitumumab) a monoclonal ... Read more

November 25, 2015November 25, 2015

AstraZeneca’s Treatment for Advanced NSCLC Is Approved by FDA

Lung Cancer, News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for AstraZeneca’s Tagrisso (osimertinib), an oral prescription for the treatment of patients with advanced non-small cell lung cancer (NSCLC). The drug is ... Read more

November 23, 2015November 23, 2015

PTC Therapeutics’ CF Therapy in 2nd Fully Enrolled Phase 3 Trial

Cystic Fibrosis, News

PTC Therapeutics announced that it has completed patient enrollment in its second Phase 3 clinical trial, known as ACT CF, to evaluate Translarna™ (ataluren) as treatment for patients with nonsense mutation cystic fibrosis ... Read more

November 18, 2015

Novartis Announces Positive Data from Phase III FLAME Clinical Trial in COPD

COPD, News

Novartis recently announced positive first data from its Phase III, head-to-head FLAME clinical trial investigating the rate of chronic exacerbations in patients with obstructive pulmonary disease (COPD) after being treated with its investigational ... Read more

November 17, 2015November 18, 2015

Pulmonary Fibrosis Lung Repair Using Stem Cells Could Depend on Age of Donor

Idiopathic Pulmonary Fibrosis, News

A team of researchers from the Miller School of Medicine recently discovered that the age of a donor mouse impacts the ability of its mesenchymal stem cells (MSCs) to repair lung damage caused ... Read more